Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure- based virtual screening

被引:27
|
作者
Atatreh, Noor [1 ]
Ghattas, Mohammad A. [1 ]
Bardaweel, Sanaa K. [2 ]
Al Rawashdeh, Sara [1 ]
Al Sorkhy, Mohammad [1 ]
机构
[1] Al Ain Univ Sci & Technol, Dept Pharmaceut Sci, Coll Pharm, Al Ain, U Arab Emirates
[2] Univ Jordan, Dept Pharmaceut Sci, Sch Pharm, Amman 11942, Jordan
来源
DRUG DESIGN DEVELOPMENT AND THERAPY | 2018年 / 12卷
关键词
protein-protein interaction; virtual screening; Mdm2; p53; anticancer; docking; pharmacophore; ELISA; P53-MDM2; INTERACTION; P53; PATHWAY; CANCER; DISCOVERY; DESIGN; POTENT;
D O I
10.2147/DDDT.S182444
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: The tumor suppressor protein p53 plays an important role in preventing tumor formation and progression through its involvement in cell division control and initiation of apoptosis. Mdm2 protein controls the activity of p53 protein through working as ubiquitin E3 ligase promoting p53 degradation through the proteasome degradation pathway. Inhibitors for Mdm2-p53 interaction have restored the activity of p53 protein and induced cancer fighting properties in the cell. Purpose: The objective of this study is to use computer-aided drug discovery techniques to search for new Mdm2-p53 interaction inhibitors. Methods: A set of pharmacophoric features were created based on a standard Mdm , inhibitor and this was used to screen a commercial drug-like ligand library; then potential inhibitors were docked and ranked in a multi-step protocol using GLIDE. Top ranked ligands from docking were evaluated for their inhibition activity of Mdm2-p53 interaction using ELISA testing. Results: Several compounds showed inhibition activity at the submicromolar level, which is comparable to the standard inhibitor Nutlin-3a. Furthermore, the discovered inhibitors were evaluated for their anticancer activities against different breast cancer cell lines, and they showed an interesting inhibition pattern. Conclusion: The reported inhibitors can represent a starting point for further SAR studies in the future and can help in the discovery of new anticancer agents.
引用
收藏
页码:3741 / 3752
页数:12
相关论文
共 50 条
  • [41] Rational Design and Binding Mode Duality of MDM2-p53 Inhibitors
    de Turiso, Felix Gonzalez-Lopez
    Sun, Daqing
    Rew, Yosup
    Bartberger, Michael D.
    Beck, Hilary P.
    Canon, Jude
    Chen, Ada
    Chow, David
    Correll, Tiffany L.
    Huang, Xin
    Julian, Lisa D.
    Kayser, Frank
    Lo, Mei-Chu
    Long, Alexander M.
    McMinn, Dustin
    Oliner, Jonathan D.
    Osgood, Tao
    Powers, Jay P.
    Saiki, Anne Y.
    Schneider, Steve
    Shaffer, Paul
    Xiao, Shou-Hua
    Yakowec, Peter
    Yan, Xuelei
    Ye, Qiuping
    Yu, Dongyin
    Zhao, Xiaoning
    Zhou, Jing
    Medina, Julio C.
    Olson, Steven H.
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (10) : 4053 - 4070
  • [42] A structure-based virtual screening identifies a novel MDM2 antagonist in the activation of the p53 signaling and inhibition of tumor growth
    Hu, Qing-yong
    Li, Lei
    Li, Yu-huang
    Zhang, Hai-bo
    Deng, Tao
    Liu, Yang
    Li, Feng-tian
    Xiao, Zhi-xiong
    Cao, Yang
    ACTA PHARMACOLOGICA SINICA, 2024, : 740 - 750
  • [43] Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction
    Vaupel, Andrea
    Bold, Guido
    De Pover, Alain
    Stachyra-Valat, Therese
    Hergovich-Lisztwan, Joanna
    Kallen, Joerg
    Masuya, Keiichi
    Furet, Pascal
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (09) : 2110 - 2114
  • [44] Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges
    Wang, Shaomeng
    Zhao, Yujun
    Aguilar, Angelo
    Bernard, Denzil
    Yang, Chao-Yie
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2017, 7 (05):
  • [45] An integrated structure- and pharmacophore-based MMP-12 virtual screening
    Mohammad Ramezani
    Jamal Shamsara
    Molecular Diversity, 2018, 22 : 383 - 395
  • [46] Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
    Nag, S.
    Zhang, X.
    Srivenugopal, K. S.
    Wang, M. -H.
    Wang, W.
    Zhang, R.
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (05) : 553 - 574
  • [47] Investigation of the inhibitory mechanism of apomorphine against MDM2-p53 interaction
    Ishiba, Hiroyuki
    Noguchi, Taro
    Shu, Keitou
    Ohno, Hiroaki
    Honda, Kaori
    Kondoh, Yasumitsu
    Osada, Hiroyuki
    Fujii, Nobutaka
    Oishi, Shinya
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (11) : 2571 - 2574
  • [48] Identification of a p53-based portable degron based on the MDM2-p53 binding region
    Melvin, Adam T.
    Dumberger, Lukas D.
    Woss, Gregery S.
    Waters, Marcey L.
    Allbritton, Nancy L.
    ANALYST, 2016, 141 (02) : 570 - 578
  • [49] mRNA Display Selection of an Optimized MDM2-Binding Peptide That Potently Inhibits MDM2-p53 Interaction
    Shiheido, Hirokazu
    Takashima, Hideaki
    Doi, Nobuhide
    Yanagawa, Hiroshi
    PLOS ONE, 2011, 6 (03):
  • [50] Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction
    Zheng, Guang-hui
    Shen, Jia-jia
    Zhan, Yue-chen
    Yi, Hong
    Xue, Si-tu
    Wang, Zhen
    Ji, Xing-yue
    Li, Zhuo-rong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 81 : 277 - 288